PE20190514A1 - Proteinas de union de tipo anticuerpo biespecificas que se unen especificamente a cd3 y cd123 - Google Patents

Proteinas de union de tipo anticuerpo biespecificas que se unen especificamente a cd3 y cd123

Info

Publication number
PE20190514A1
PE20190514A1 PE2019000065A PE2019000065A PE20190514A1 PE 20190514 A1 PE20190514 A1 PE 20190514A1 PE 2019000065 A PE2019000065 A PE 2019000065A PE 2019000065 A PE2019000065 A PE 2019000065A PE 20190514 A1 PE20190514 A1 PE 20190514A1
Authority
PE
Peru
Prior art keywords
sequence seq
formula
polypeptide
bispecific antibody
amino acids
Prior art date
Application number
PE2019000065A
Other languages
English (en)
Inventor
Jana Albrecht
Christian Beil
Jochen Beninga
Katja Kroll
Christian Lange
Wulf Dirk Leuschner
Ercole Rao
Marion Schneider
Peter Wonerow
Stephane Guerif
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of PE20190514A1 publication Critical patent/PE20190514A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se refiere a una proteina de union de tipo anticuerpo que se une especificamente a CD3(epsilon) humana y CD123 humana que comprende dos cadenas polipeptidicas que forman dos sitios de union a antigeno, donde una cadena polipeptidica tiene una estructura de formula (IV) [VD1-L1-VD2-L2-CL-L5-Fc2] y la otra de formula (III) [VD3-L3-VD4-L4-CH1-Fc], en donde: la formula (IV) consiste en la secuencia de aminoacidos SEQ ID NO:71 que comprende VD1 de secuencia SEQ ID NO:54, L1 de secuencia SEQ ID NO:54, VD2 de secuencia SEQ ID NO:10, L2 de secuencia SEQ ID NO:56, CL de secuencia SEQ ID NO:18, L5 consiste en 0 aminoacidos y Fc2 consiste en la secuencia SEQ ID NO:70; y la formula (II) consiste en la secuencia de aminoacidos SEQ ID NO:67 que comprende VD3 de secuencia SEQ ID NO:9, L3 que consiste en 0 aminoacidos, VD4 de secuencia SEQ ID NO:52, L4 consiste en 0 aminoacidos, CH1 de secuencia SEQ ID NO:19 y Fc consiste en la secuencia SEQ ID NO:68, y en donde la formula polipeptidica (IV) y el polipeptido de formula (III) forman un par de cadena ligera-cadena pesada de entrecruzamiento. Tambien esta referida a una composicion farmaceutica, un acido nucleico, una celula huesped y un kit
PE2019000065A 2016-07-18 2017-07-17 Proteinas de union de tipo anticuerpo biespecificas que se unen especificamente a cd3 y cd123 PE20190514A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16305923 2016-07-18

Publications (1)

Publication Number Publication Date
PE20190514A1 true PE20190514A1 (es) 2019-04-10

Family

ID=56507555

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019000065A PE20190514A1 (es) 2016-07-18 2017-07-17 Proteinas de union de tipo anticuerpo biespecificas que se unen especificamente a cd3 y cd123

Country Status (24)

Country Link
US (1) US20190241657A1 (es)
EP (1) EP3484924A1 (es)
JP (2) JP7071329B2 (es)
KR (1) KR20190028771A (es)
CN (1) CN109715665A (es)
AR (1) AR109264A1 (es)
AU (1) AU2017299125A1 (es)
BR (1) BR112019000770A2 (es)
CA (1) CA3030943A1 (es)
CL (1) CL2019000119A1 (es)
CO (1) CO2019001367A2 (es)
CR (1) CR20190072A (es)
DO (1) DOP2019000011A (es)
EA (1) EA201990321A1 (es)
EC (1) ECSP19011185A (es)
IL (1) IL264248A (es)
MA (1) MA45680A (es)
MX (1) MX2019000844A (es)
PE (1) PE20190514A1 (es)
PH (1) PH12019500122A1 (es)
SG (1) SG11201900400QA (es)
TN (1) TN2019000015A1 (es)
TW (1) TWI790206B (es)
WO (1) WO2018015340A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3247725T (pt) 2015-01-23 2020-10-07 Sanofi Sa Anticorpos anti-cd3, anticorpos anti-cd123 e anticorpos biespecíficos que se ligam de forma biespecífica a cd3 e/ou a cd123
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
EA039859B1 (ru) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
TWI790206B (zh) * 2016-07-18 2023-01-21 法商賽諾菲公司 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白
MX2021004868A (es) * 2018-10-30 2021-09-08 Macrogenics Inc Diacuerpos cd123 x cd3 biespecificos para el tratamiento de neoplasias hematologicas.
CN113874400A (zh) * 2019-03-11 2021-12-31 詹森生物科技公司 抗Vβ17/抗CD123双特异性抗体
CN111171155B (zh) * 2020-02-05 2021-02-19 北京智仁美博生物科技有限公司 抗cd3和cd123双特异性抗体及其用途
TW202200619A (zh) * 2020-03-17 2022-01-01 美商西雅圖免疫公司 引導及導航控制(gnc)抗體樣蛋白質及製造與使用其之方法
US11965024B2 (en) 2020-09-11 2024-04-23 Janssen Biotech, Inc. Methods and compositions for modulating beta chain mediated immunity
JP2024506831A (ja) 2021-01-28 2024-02-15 リジェネロン・ファーマシューティカルズ・インコーポレイテッド サイトカイン放出症候群を治療するための組成物及び方法
CN113368232B (zh) * 2021-06-02 2022-08-26 上海交通大学 多特异性抗原结合蛋白及其应用
WO2023012367A1 (en) * 2021-08-06 2023-02-09 Universität Basel Discernible cell surface protein variants for use in cell therapy
AU2023254191A1 (en) 2022-04-11 2024-10-17 Regeneron Pharmaceuticals, Inc. Compositions and methods for universal tumor cell killing
US20240277844A1 (en) 2023-02-17 2024-08-22 Regeneron Pharmaceuticals, Inc. Induced nk cells responsive to cd3/taa bispecific antibodies

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4361549A (en) 1979-04-26 1982-11-30 Ortho Pharmaceutical Corporation Complement-fixing monoclonal antibody to human T cells, and methods of preparing same
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
AU6642390A (en) 1989-10-27 1991-05-31 Arch Development Corporation Methods and compositions for promoting immunopotentiation
US6406696B1 (en) 1989-10-27 2002-06-18 Tolerance Therapeutics, Inc. Methods of stimulating the immune system with anti-CD3 antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
JP3298879B2 (ja) 1990-12-20 2002-07-08 イグジス，インコーポレイテッド 結合タンパク質の最適化
DE69434860T2 (de) 1993-02-22 2007-03-15 The Rockefeller University Herstellung von helfer-freien retroviren mit hohem titer mittels transienter transfektion
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
FR2712812B1 (fr) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition pour la production de produits thérapeutiques in vivo.
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
AU690474B2 (en) 1995-09-11 1998-04-23 Kyowa Hakko Kirin Co., Ltd. Antibody againts alpha-chain of human interleukin 5 receptor
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
WO1997024373A1 (en) 1995-12-29 1997-07-10 Medvet Science Pty. Limited Monoclonal antibody antagonists to haemopoietic growth factors
DE19721700C1 (de) 1997-05-23 1998-11-19 Deutsches Krebsforsch Mutierter OKT3-Antikörper
NZ507381A (en) 1998-04-21 2003-12-19 Micromet Ag CD19xCD3 specific polypeptides and uses thereof
CA2895884C (en) 2000-03-06 2019-04-23 University Of Kentucky Research Foundation A compound that selectively binds to cd123 and use thereof to kill hematologic cancer progenitor cells
SG10201407388XA (en) 2007-08-29 2015-01-29 Sanofi Aventis Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
AU2009299791B2 (en) * 2008-10-01 2016-02-25 Amgen Research (Munich) Gmbh Cross-species-specific PSCAxCD3, CD19xCD3, C-METxCD3, EndosialinxCD3, EpCAMxC D3, IGF-1RxCD3 or FAPalpha xCD3 bispecific single chain antibody
TWI838039B (zh) 2011-03-28 2024-04-01 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
PE20141521A1 (es) 2011-08-23 2014-10-25 Roche Glycart Ag Moleculas biespecificas de union a antigeno activadoras de celulas t
ES2924722T3 (es) * 2012-05-18 2022-10-10 Aptevo Res & Development Llc Unión de inmunofusión de scFv biespecífico (BIf) a CD123 y CD3
EP2839842A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
MX2016006741A (es) * 2013-12-10 2016-08-12 Hoffmann La Roche Uso del dominio de union de una subunidad de una estructura de multiples subunidades para la liberacion dirigida de entidades farmaceuticamente activas a la estructura de multiples subunidades.
HUE048791T2 (hu) * 2014-09-05 2020-09-28 Janssen Pharmaceutica Nv CD123 kötõszerek és alkalmazásaik
CN110894240B (zh) * 2014-11-26 2022-04-15 森科股份有限公司 结合cd3和肿瘤抗原的异二聚体抗体
PT3247725T (pt) * 2015-01-23 2020-10-07 Sanofi Sa Anticorpos anti-cd3, anticorpos anti-cd123 e anticorpos biespecíficos que se ligam de forma biespecífica a cd3 e/ou a cd123
TWI790206B (zh) * 2016-07-18 2023-01-21 法商賽諾菲公司 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白

Also Published As

Publication number Publication date
SG11201900400QA (en) 2019-02-27
CR20190072A (es) 2019-06-25
EA201990321A1 (ru) 2019-06-28
IL264248A (en) 2019-02-28
WO2018015340A1 (en) 2018-01-25
MA45680A (fr) 2019-05-22
MX2019000844A (es) 2019-07-04
US20190241657A1 (en) 2019-08-08
PH12019500122A1 (en) 2019-04-15
AU2017299125A1 (en) 2019-03-07
ECSP19011185A (es) 2019-02-28
KR20190028771A (ko) 2019-03-19
AR109264A1 (es) 2018-11-14
CL2019000119A1 (es) 2019-06-14
CO2019001367A2 (es) 2019-02-19
BR112019000770A2 (pt) 2019-07-02
CN109715665A (zh) 2019-05-03
JP2019531701A (ja) 2019-11-07
DOP2019000011A (es) 2019-05-15
TN2019000015A1 (en) 2020-07-15
JP2022105138A (ja) 2022-07-12
JP7071329B2 (ja) 2022-05-18
CA3030943A1 (en) 2018-01-25
TWI790206B (zh) 2023-01-21
EP3484924A1 (en) 2019-05-22
TW201811830A (zh) 2018-04-01

Similar Documents

Publication Publication Date Title
PE20190514A1 (es) Proteinas de union de tipo anticuerpo biespecificas que se unen especificamente a cd3 y cd123
AR111361A1 (es) Anticuerpos biespecíficos de unión específica a pd1 y lag3
HRP20201517T1 (hr) Anti-cd3 protutijela, anti-cd123 protutijela i bispecifična protutijela koja se specifično vežu na cd3 i/ili cd123
AR077088A1 (es) Proteinas biespecificas de union a antigeno
EA201990570A1 (ru) Моноклональное антитело против pd1, его фармацевтическая композиция и их применение
PE20130205A1 (es) Proteinas de union a il-1
HRP20191470T1 (hr) Heterodimerni proteini
AR080793A1 (es) Anticuerpos biespecificos
BR112015000798A2 (pt) heterodímeros assimétricos biespecíficos compreendendo construtos anti-cd3
PE20181044A1 (es) Anticuerpos anti-pd-1 y composiciones
EA200870555A1 (ru) Слитые белки, их применение и способы их получения
PE20212205A1 (es) Proteinas de union condicionalmente activadas restringidas
AR112419A1 (es) Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
PE20221021A1 (es) Proteinas de union a antigeno que se unen especificamente a mage-a
AR076797A1 (es) Anticuerpos triespecificos o tetraespecificos
NZ608773A (en) Specific binding proteins and uses thereof
AR091069A1 (es) Proteinas de union a antigeno dirigidas contra el receptor st2
PE20091172A1 (es) Anticuerpos bivalentes biespecificos
FI3683235T3 (fi) Anti-IL-33-vasta-aineita ja niiden käyttöjä
AR083672A1 (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
EA201990018A1 (ru) Антитела к с5 и способы их применения
EA201591153A1 (ru) Антитела, связывающиеся с tl1a, и их применение
EA201891410A1 (ru) Антитела к с5 и способы их применения
PE20141658A1 (es) Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3)
RS53175B (en) IL-4 AND / OR IL-13 BINDING ANTIBODIES AND THEIR USES

Legal Events

Date Code Title Description
FA Abandonment or withdrawal